title: Pneumococcal capsular antigen detection and pneumococcal serology in patients with community acquired pneumonia.
abstract: BACKGROUND
  Methods to determine the microbial cause of community acquired pneumonia include detection of pneumococcal antigen and measurement of pneumococcal capsular antibody response. Their usefulness compared with conventional microbiological techniques was investigated in patients with pneumonia, some of whom had been treated with antibiotics.
  
  
  METHODS
  Pneumococcal capsular antigen was detected by latex agglutination in sputum and the results compared prospectively with results of conventional microbiological techniques in 90 patients with community acquired pneumonia. Serum, urine, and pleural fluid samples were also tested for antigen. Serum pneumococcal capsular antibody titres were measured.
  
  
  RESULTS
  A diagnosis was established by conventional microbiological techniques in 53 patients, 30 of whom had pneumococcal pneumonia. The sensitivity of antigen detection in first day sputum specimens (n = 18) in those with pneumococcal pneumonia was 94%; antigen was present in 23 of the 27 patients who produced representative sputum on admission and during follow up. The specificity of antigen detection in sputum in patients with non-pneumococcal pneumonia and lung infarction was 87%. Antigen was present in 12 of 25 patients with pneumonia of unknown aetiology who produced representative sputum. Antigen was rarely detected in serum and urine, but was present in pleural fluid in three of four patients with pneumococcal pneumonia and in all four patients with pneumonia of unknown aetiology. Pneumococcal antigen remained detectable in patients treated with antibiotics. Pneumococcal capsular antibody detection was as specific (85%) as antigen detection, but had a lower sensitivity (50%).
  
  
  CONCLUSIONS
  Pneumococcal antigen detection in sputum or pleural fluid is of value in making a rapid diagnosis and provides an additional diagnostic result in patients with pneumococcal pneumonia, especially those receiving antibiotic treatment.
authors.affiliation: Department of Pulmonary Diseases, University Hospital, Groningen, Netherlands.
authors.forename: W G
authors.initials: WG
authors.lastname: Boersma
authors.forename: A
authors.initials: A
authors.lastname: Löwenberg
authors.forename: Y
authors.initials: Y
authors.lastname: Holloway
authors.forename: H
authors.initials: H
authors.lastname: Kuttschrütter
authors.forename: J A
authors.initials: JA
authors.lastname: Snijder
authors.forename: G H
authors.initials: GH
authors.lastname: Koëter
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000942:Antigens, Bacterial / Q000032:analysis*; D000954:Antigens, Surface / Q000032:analysis*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011018:Pneumonia, Pneumococcal / Q000188:drug therapy / Q000209:etiology / Q000276:immunology* / Q000382:microbiology; D013183:Sputum / Q000382:microbiology; D013296:Streptococcus pneumoniae / Q000276:immunology* / Q000302:isolation & purification
chemical_list: D000900:Anti-Bacterial Agents; D000942:Antigens, Bacterial; D000954:Antigens, Surface